HEIDELBERG, Germany, Jan. 14, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD ), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that Dr. Andrew Evens has joined Affimed's Scientific Advisory Board. Dr. Evens is Professor of Medicine at Tufts University School of Medicine and he is Chief of the Division of Hematology/Oncology and Director of the Tufts Cancer Center at Tufts Medical Center in Boston, Massachusetts. He was also named the Chan Soon-Shiong Endowed Scholar in Precision Medicine at Tufts Medical Center.
"We are pleased and honored to have added Dr. Evens to our Scientific Advisory Board," said Jens-Peter Marschner, M.D., CMO of Affimed. "Dr. Evens brings invaluable expertise in the field of hematological malignancies, including translational work and clinical trial design, which will be extremely important as the Company moves forward towards mid-stage and registrational studies with its two lead pipeline candidates, which are currently in Phase II and Phase I trials."
Dr. Evens completed his Hematology/Oncology fellowship at Northwestern University Feinberg School of Medicine and The Robert H. Lurie Comprehensive Cancer Center (RHLCCC) where he also remained on faculty for approximately 15 years. Before arriving to Tufts Medical Center, he was a faculty member at the University of Massachusetts Medical School and the UMass Memorial Cancer Center where he served as the Deputy Director for the Cancer Center. Dr. Evens' focus is in the biology, prognosis and treatment of Non-Hodgkin lymphoma and Hodgkin disease/lymphoma. He has designed and conducted a multitude of clinical trials in lymphoid malignancies and has authored or co-authored more than 100 original articles in this field. Dr. Evens also maintains a R01-funded translational lymphoma laboratory examining lymphoma biology, signal transduction pathways, free radical-mediated biology and the development of novel targeted agents for the treatment of lymphoma. Additionally, Dr. Evens is an Associate Editor for the British Journal of Haematology; he chairs the Hematology Panel for the VA R01 Scientific Merit Review committee; and he is a primary member of the Hodgkin Lymphoma Working Group for the NIH and NCI Steering Committee.
About Affimed N.V.
Affimed (Nasdaq: AFMD ) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com .
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in Affimed's filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
Affimed N.V. Caroline Stewart, Head IR & Communication Phone: +1 347394 6793 E-Mail: or Media requests: Stephanie May or Gretchen Schweitzer MacDougall Biomedical Communications Phone: +49 89 2424 3494 or +49 172 861 8540 E-Mail:
